Business
Allakos: Prevalence Data Shows A Large Undiagnosed Market (NASDAQ:ALLK)
Allakos has a molecule targeting a largely undiagnosed market. If their prevalence study is any good, the potential for the therapy is huge.
Allakos has a molecule targeting a largely undiagnosed market. If their prevalence study is any good, the potential for the therapy is huge.
